Skip to main content

SYNERGIE : Q3 2026 REVENUES

PRESS RELEASE | October 21st, 2026 – 5.45pm Q3 2026 REVENUE SYNERGIE continues its growth momentum in the third quarter of 2026 and reports revenue of €917.2 million, up 11.2% (+2.4% on a like-for-like basis)in € m Q3 2026 Q3 2025 Variation 9M 2026 9M 2025 VariationInternational 601.2 505.1 +19.0% 1,688.9 1,462.6 15.5%France 316.0 319.9 -1.2% 938.8 946.0 -0.8%Total 917.2 825.0 +11.2% 2,627.7 2,408.6 +9.1%SYNERGIE reported third-quarter 2026 revenue of €917.2 million, up 11.2% compared with the same period in 2025 (+2.4% on a like-for-like basis). For the first nine months of the year, revenue amounted to €2,627.7 million, representing a growth of 9.1% (+2.3% at constant scope and exchange rates). This increase is mainly due to the acquisitions completed in Switzerland and Canada. International operations now account for...

Continue reading

BrightFlixx Finance (Luxembourg) S.A. Commences Cash Tender Offer For All Outstanding Shares of Cavitation Technologies, Inc. and Concurrent Cash Tender Offer For All Outstanding Shares of Alchemy Beverages Inc.

EXHIBIT (a)(5)(A)  NEWS RELEASE ANNOUNCING TENDER OFFERS  LUXEMBOURG, Oct. 21, 2026 (GLOBE NEWSWIRE) — BrightFlixx Finance (Luxembourg) S.A., a Luxembourg public limited company (société anonyme) (the “Purchaser”), today announced that it has commenced two concurrent cash tender offers. In the first offer, the Purchaser is offering to purchase all outstanding shares of common stock (the “CVAT Shares”) of Cavitation Technologies, Inc., a Nevada corporation (the “Company”). In the second offer, the Purchaser is offering to purchase all outstanding shares of common stock (the “ABI Shares”) of Alchemy Beverages Inc., a privately held Delaware corporation affiliated with the Company (“Alchemy”). SHAREHOLDER INFORMATION WEBSITE: https://brightflixx.capital/ CAVITATION TECHNOLOGIES, INC. — THE OFFER Final Offer Price and Record Date...

Continue reading

Ping An Biomedical Announces 1-for-40 Reverse Stock Split

Class A Ordinary Shares Expected to Begin Trading on a Split-Adjusted Basis on October 23, 2026 HONG KONG, Oct. 21, 2026 (GLOBE NEWSWIRE) — Ping An Biomedical Co., Ltd. (Nasdaq: PASW) (“Ping An Bio” or the “Company”) announced that its board of directors has approved a 1-for-40 reverse stock split of the Company’s class A ordinary shares and class B ordinary shares. The Company’s class A ordinary shares are expected to begin trading on a split-adjusted basis on the Nasdaq Capital Market at the opening of trading on October 23, 2026. The shares will continue to trade under the ticker symbol “PASW.” At the extraordinary general meeting (the “EGM”) of shareholders of the Company held on 18 March 2026, at 9:00 a.m., Hong Kong Time, the following matters, among others, were approved and authorized that with effect on a date within one...

Continue reading

Alignment Health Expands Medicare Advantage Plan to Nye County for 2027

Expansion extends Alignment’s Nevada presence to three counties, home to more than 554,000 Medicare beneficiaries LAS VEGAS, Oct. 21, 2026 (GLOBE NEWSWIRE) — Alignment Health Plan, an award-winning Medicare Advantage plan from Alignment Health, today announced it will expand into Nye County beginning Jan. 1, 2027, offering new Medicare Advantage plan options to local seniors. With the expansion, Alignment Health Plan will serve Clark, Nye and Washoe counties, which are home to more than 554,000 Medicare beneficiaries, according to the Centers for Medicare & Medicaid Services (CMS) data1. With the addition of Nye County, Alignment Health’s 2027 Nevada portfolio features six Medicare Advantage plans across three counties supported by more than 6,500 physicians and access to premier provider partners. People with Medicare living...

Continue reading

Novartis receives European Commission approval for Cosentyx® in polymyalgia rheumatica (PMR) 

Cosentyx® (secukinumab) becomes first and only IL-17A inhibitor approved in Europe for adults with PMR,1 a common inflammatory rheumatic disease with limited advanced treatment options2-6 Approval based on Phase III REPLENISH trial showing Cosentyx doubled sustained remission rates vs placebo at Week 52; safety results consistent with established Cosentyx profile7 Additional regulatory reviews of Cosentyx in PMR ongoing globally, including in US and JapanBasel, October 21, 2026 – Novartis announced today that the European Commission (EC) has approved Cosentyx® (secukinumab) for the treatment of adults with polymyalgia rheumatica (PMR) who have had an inadequate response to glucocorticoids or who experience relapse during glucocorticoid taper. With this approval, Cosentyx becomes the first and only interleukin-17A (IL-17A) inhibitor...

Continue reading

National Advertising Division Recommends Virgin Cruises Modify Virgin Voyages Advertising to Clearly and Conspicuously Disclose Service Gratuities

As part of its routine, ongoing monitoring program, BBB National Programs’ National Advertising Division recommended that Virgin Cruises Intermediate Limited Inc. modify its Virgin Voyages advertising to clearly and conspicuously disclose service gratuities throughout the checkout process. McLean, VA, Oct. 21, 2026 (GLOBE NEWSWIRE) — As part of its routine, ongoing monitoring program, BBB National Programs’ National Advertising Division recommended that Virgin Cruises Intermediate Limited Inc. modify its Virgin Voyages advertising to clearly and conspicuously disclose service gratuities throughout the checkout process. Virgin Voyages is an adults-only cruise line. At issue for the National Advertising Division (NAD) was whether Virgin Cruises highlighted a lead price without prominently disclosing the additional, mandatory per-night...

Continue reading

Progyny, Inc. Announces Details for Its Third Quarter 2026 Results Report

NEW YORK, Oct. 21, 2026 (GLOBE NEWSWIRE) — Progyny, Inc. (Nasdaq: PGNY), a global leader in women’s health and family building solutions, will report its financial results for the quarterly period ended September 30, 2026, after the close of the market on Wednesday, November 4, 2026. The company will host a conference call at 4:45 p.m. Eastern Time (1:45 p.m. Pacific Time) and issue a press release regarding its financial results prior to the start of the call. Interested participants in the United States may access the conference call by dialing 1.866.825.7331 and using the passcode 265484. International participants may access the call by dialing 1.973.413.6106 and using the same passcode. An audio replay of the call will be available through Wednesday, November 11, 2026, and may be accessed by dialing 1.800.332.6854 (U.S. participants)...

Continue reading

Toll Brothers Announces Waterford Pointe Community Now Open in Piedmont, South Carolina

Exclusive boutique community offers luxury homes on estate-sized home sites along the Saluda River PIEDMONT, S.C., Oct. 21, 2026 (GLOBE NEWSWIRE) — Toll Brothers, Inc. (NYSE:TOL), the nation’s leading builder of luxury homes, today announced the grand opening of Waterford Pointe, an intimate community of 28 luxury homes on expansive wooded home sites adjacent to the Saluda River in the Piedmont area of Powdersville, South Carolina. The Sales Center is now open at 201 Waterford Pointe Drive in Piedmont. Waterford Pointe features luxury single-family home designs ranging from 3,645 to 4,680+ square feet with 4 to 5 bedrooms and 3.5 to 5.5 bathrooms. These exquisite homes are situated on expansive, estate-sized home sites of up to three acres, with some offering beautiful water views of the Saluda River. Homes are priced from...

Continue reading

Selection announced for a member of the Management Board of “Ignitis grupė” responsible for Energy Markets and Commerce

AB “Ignitis grupė” (hereinafter – the Group) informs that a selection has been announced for a member of the Group’s Management Board responsible for the competence area of Energy Markets and Commerce. This area is currently overseen by Management Board member Vytenis Koryzna, who is expected to assume the positions of the Group’s CEO and Chair of the Management Board on 1 March 2027. The Group’s Supervisory Board plans to make the final decision on his appointment soon. The selected Management Board member will take over the competence area currently overseen by V. Koryzna. V. Koryzna will take over as the Group’s CEO and Chair of the Management Board following the expiry of Darius Maikštėnas’s second term of office on 28 February 2027. The selection aims to ensure a full five-member Management Board and continuity in the oversight of...

Continue reading

Selection announced for a member of the Management Board of “Ignitis grupė” responsible for Energy Markets and Commerce

AB “Ignitis grupė” (hereinafter – the Group) informs that a selection has been announced for a member of the Group’s Management Board responsible for the competence area of Energy Markets and Commerce. This area is currently overseen by Management Board member Vytenis Koryzna, who is expected to assume the positions of the Group’s CEO and Chair of the Management Board on 1 March 2027. The Group’s Supervisory Board plans to make the final decision on his appointment soon. The selected Management Board member will take over the competence area currently overseen by V. Koryzna. V. Koryzna will take over as the Group’s CEO and Chair of the Management Board following the expiry of Darius Maikštėnas’s second term of office on 28 February 2027. The selection aims to ensure a full five-member Management Board and continuity in the oversight of...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.